Other Information
−Removed: (c) During the quarter ended March 31, 2026, no
−Removed: director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading
−Removed: arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
−Removed: The following exhibits are filed as part of, or
−Removed: incorporated by reference into, this Quarterly Report.
−Removed: Description of Exhibit
−Removed: Amended and Restated Certificate of Incorporation of Apimeds Pharmaceuticals US, Inc.
−Removed: (incorporated by reference to our Schedule 14C filed on February 27, 2026).
−Removed: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Apimeds Pharmaceuticals US, Inc.
−Removed: (incorporated by reference to our Schedule 14C filed on February 27, 2026).
−Removed: Amended and Restated Bylaws of Apimeds Pharmaceuticals US, Inc.
−Removed: (incorporated by reference to Exhibit 3.3 to our Annual Report on Form 10-K filed on April 15, 2025)
−Removed: Amended and Restated Bylaws of Apimeds Pharmaceuticals US, Inc.
−Removed: (incorporated by reference to our Schedule 14C filed on February 27, 2026).
−Removed: Financial Advisory Agreement dated December 1, 2025.
−Removed: Rule 13a-14(a) Certification by Principal Executive Officer
−Removed: Rule 13a-14(a) Certification by Principal Financial and Accounting Officer
−Removed: Section 1350 Certification of Principal Executive Officer
−Removed: Section 1350 Certification of Principal Financial and Accounting Officer
−Removed: Inline XBRL Instance Document
−Removed: Inline XBRL Taxonomy Extension Schema Document
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase Document
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase Document
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document
−Removed: Inline XBRL Taxonomy Extension Presentation Linkbase Document
−Removed: Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101)
−Removed: or furnished with this Quarterly Report.
−Removed: Pursuant to the requirements of the Securities
−Removed: Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: During the three months ended June 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
+Added: 3.1 Certificate of Amendment to the Certificate of Incorporation, effective July 23, 2026.
+Added: 10.1 Confidential Settlement Agreement and Mutual Release, dated April 24, 2026 (incorporated by reference to the Company’s Current Report on Form 8-K filed May 4, 2026).
+Added: 31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: 31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: 31.3 Certification of Co-Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: 32.1 Certification of Principal Executive Officers and Principal Financial Officer pursuant to 18 U.S.C.
+Added: Section 1350.
+Added: 101 Inline XBRL documents.
+Added: 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
APIMEDS PHARMACEUTICALS US, INC.
−Removed: /s/ Erick Frim
−Removed: Chief Financial Officer
−Removed: (Principal Financial and Accounting Officer)
+Added: Vin Menon, Co-Chief Executive Officer
+Added: (Principal Executive Officer)
+Added: / s / Sungjoon Chae
+Added: Sungjoon Chae, Co-Chief Executive Officer
+Added: (Principal Executive Officer)
+Added: / s / Erick Frimm
+Added: Erick Frim, Chief Financial Officer
+Added: (Principal Financial Officer)
+Added: August 14, 2026
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.